N-(磺甲基)-D-谷氨酰胺 | 90237-02-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(磺甲基)-D-谷氨酰胺
• 英文名称: N-(Sulfomethyl)-D-glutamine
• 英文别名: (2R)-2-amino-5-oxo-5-(sulfomethylamino)pentanoic acid
• CAS: 90237-02-8
• 化学式: C₆H₁₂N₂O₆S
• 分子量: 240.24
• InChiKey: HCMBCMVOCRJSME-SCSAIBSYSA-N

物化性质

• 熔点：
  216-218 °C
• 密度：
  1.593±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于水中

计算性质

• 辛醇/水分配系数(LogP)：
  -4.8
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  155
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
  申请人：Kõster Hubert

  公开号：US20100248264A1

  公开（公告）日：2010-09-30

  Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Automated systems for performing the methods also are provided.

  提供了捕获化合物及其集合以及使用这些化合物进行生物分子分析的方法。特别地，提供了用于分析复杂蛋白质混合物（如蛋白质组）的集合、化合物和方法。这些化合物是多功能试剂，可用于分离和分离复杂的蛋白质混合物。还提供了执行这些方法的自动化系统。
• New use of glutamate antagonists for the treatment of cancer
  申请人：Ikonomidou, Hrissanthi

  公开号：EP1002535A1

  公开（公告）日：2000-05-24

  New therapies can be devised based upon a demonstration of the role of glutamate in the pathogenesis of cancer. Inhibitors of the interaction of glutamate with the AMPA, kainate, or NMDA receptor complexes are likely to be useful in treating cancer and can be formulated as pharmaceutical compositions. They can be identified by appropriate screens.

  根据谷氨酸在癌症发病机制中的作用，可以设计出新的疗法。谷氨酸与 AMPA、kainate 或 NMDA 受体复合物相互作用的抑制剂可能有助于治疗癌症，并可配制成药物组合物。它们可以通过适当的筛选来确定。
• Use of GABA B receptor agonists for the treatment of hyperkinesia and poriomania
  申请人：Ajinomoto Co., Ltd.

  公开号：EP1138332A1

  公开（公告）日：2001-10-04

  It is an object of the present invention to provide a pharmaceutical composition, which permits the inhibition of non-intentional motions such as poriomania and hyperkinesia without any inhibition of intentional motions and in particular to provide a pharmaceutical composition capable of treating patients suffering from, for instance, poriomania and hyperkinesia. Moreover, it is also an object of the present invention to provide a method of using running neuron-inhibitory substances. A pharmaceutical composition for treating a patient suffering from symptoms accompanied by non-intentional motions such as poriomania and hyperkinesia, comprising a substance capable of pre-synaptically or post- synaptically inhibiting the running neurons. A method of using such substances permits the preparation of a pharmaceutical composition for treating a patient suffering from symptoms accompanied with unintentional motions such as poriomania and hyperkinesia. In particular, the pharmaceutical composition comprises a member selected from the group consisting of GABAB receptor agonists, GABAA receptor agonists, and GABAA receptor-enhancing substances, or any combination thereof. Moreover, the foregoing problems can likewise be solved by providing a method of using such running neuron-inhibitory substances, which permits the preparation of a pharmaceutical composition for treating a patient suffering from the foregoing symptoms.

  本发明的目的是提供一种药物组合物，该药物组合物能够抑制非蓄意运动，例如多孔症和运动过度，而不抑制蓄意运动，特别是提供一种能够治疗多孔症和运动过度等患者的药物组合物。此外，本发明的另一个目的是提供一种使用运行神经元抑制物质的方法。 一种药物组合物，用于治疗患有诸如多孔症和运动机能亢进症等伴随非意愿运动症状的患者，该药物组合物包含一种能够在突触前或突触后抑制奔跑神经元的物质。使用这类物质的方法可以制备出一种药物组合物，用于治疗患有诸如多孔症和运动过度等伴随无意运动症状的患者。特别是，药物组合物包含选自 GABAB 受体激动剂、GABAA 受体激动剂和 GABAA 受体增强物质或其任意组合的成员。此外，通过提供一种使用这种运行神经元抑制物质的方法，同样可以解决上述问题，该方法允许制备一种药物组合物，用于治疗患有上述症状的患者。
• Pharmaceutical compositions for preventing problem behaviour of companion animals
  申请人：Ajinomoto Co., Inc.

  公开号：EP1270002A2

  公开（公告）日：2003-01-02

  The present invention provides a pharmaceutical composition and a method for prevent problem behaviors of animals, particularly companion animals. The pharmaceutical composition comprises one or more running neuron inhibiting substances, such as GABAB receptor agonists, GABAA receptor agonists, substances that enhance the activity of GABAA receptor and kainate receptor antagonists, or any combination thereof. The method comprises the step of administrating the pharmaceutical composition of the present invention.

  本发明提供了一种药物组合物和一种预防动物，特别是伴侣动物问题行为的方法。该药物组合物包含一种或多种运行神经元抑制物质，如 GABAB 受体激动剂、GABAA 受体激动剂、增强 GABAA 受体活性的物质和 kainate 受体拮抗剂，或它们的任意组合。该方法包括施用本发明药物组合物的步骤。
• METHOD OF FATTENING POULTRY
  申请人：Ajinomoto Co., Inc.

  公开号：EP1452096A1

  公开（公告）日：2004-09-01

  A method of fattening fowls comprising the step of administrating one or more running neuron inhibitory substance(s) is provided. Especially, a method of fattening fowls is provided, wherein fowls are administrated by a substance selected from the group consisting of GABAB receptor agonist, GABAA receptor agonist, GABAA receptor enhancer, kainate receptor antagonist and a combination thereof or fowls are provide with a feed comprising the substance or a combination thereof.

  本发明提供了一种肥育家禽的方法，包括施用一种或多种运行神经元抑制物质的步骤。特别是，本发明提供了一种育肥家禽的方法，其中向家禽施用选自 GABAB 受体激动剂、GABAA 受体激动剂、GABAA 受体增强剂、kainate 受体拮抗剂及其组合的物质，或向家禽提供含有该物质或其组合的饲料。